
Browse procurement-ready healthcare products from trusted vendors across the Afya Chain marketplace.
Formulations: - Parenteral > General injections > IV: 500 µg per mL in 1 mL ampoule (as sulfate); 500 µg per mL in 5 mL ampoule (as sulfate) Respiratory > Inhalation > solution: 100 µg per actuation in pressurized metered dose inhaler (as sulfate); 2.5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per mL in multi-dose bottle (as sulfate) for use in nebulizers Indications: - Chronic obstructive pulmonary disease - Asthma Source: EML workbook import
Indications: - Chronic obstructive pulmonary disease - Asthma Source: EML workbook import
Formulations: - Respiratory > Inhalation > powder: 18 µg in capsule Respiratory > Inhalation > solution: 1.25 µg per actuation in soft mist inhaler; 2.5 µg per actuation in soft mist inhaler Indications: - Chronic obstructive pulmonary disease Source: EML workbook import
Indications: - Chronic obstructive pulmonary disease Source: EML workbook import
Formulations: - Oral > Liquid: 50 mg granules for oral suspension Indications: - Unspecified injury, poisoning or certain other consequences of external causes Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule Oral > Liquid: 10%; 20% Indications: - Acute or subacute hepatic failure - Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs Source: EML workbook import
Formulations: - Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate) Indications: - Anterior uveitis Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule or vial (10%) - Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule Indications: - Hypermagnesaemia - Tetany due to acute calcium deficiency Source: EML workbook import
Formulations: - Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate) Indications: - Harmful effects of drugs, medicaments or biological substances, not elsewhere classified - Other specified sickle cell disorders or other haemoglobinopathies - Thalassaemias Source: EML workbook import
Formulations: - Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule; 100 mg per mL in 3 mL ampoule Indications: - Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified Source: EML workbook import
Ready to amplify your rewards? Drop your email and we'll be in touch soon.